GlobalData on MSN1d
Metsera raises $215m in Series B round for weight loss candidatesMetsera has brought in over $500m in funding in just seven months as it looks to enter the competitive weight loss arena.
Metsera is riding the wave of continued enthusiasm for GLP-1 drugs and its own early-stage data to bring in a hefty $215 ...
The sizeable new round follows the announcement of phase 1 data for its lead asset MET-097i in September and, according to ...
With promising Phase 1 results in hand, Metsera hopes to develop a longer-lasting GLP-1 injection along with other types of ...
Despite crowding in the next-gen weight loss space, Metsera has raised over $500 million since its April launch, indicating a ...
AstraZeneca and Amgen announced that a Phase 3 trial of Tezspire (tezepelumab) showed a statistically significant and ...
NEW YORK--(BUSINESS WIRE)--Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced the close of a ...
Plus: How AI can make it easier to find drugs from nature and a study suggests Ozempic could treat alcoholism.
with a readout expected before the end of the year. Other players include Metsera, a newly emerged weight loss biotech that ...
Just seven months after unveiling with $290 million, obesity biotech Metsera is back with another $215 million.
Kebilidi is the first gene therapy approved by the FDA for administration directly into the brain, given via a cannula during ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback